NOTCH1 and neoplasm: Practically, our data suggest that a NOTCH1-ICD IHC assay could be implemented in the clinic, as it is tumor specific, and NOTCH1-ICD is expressed in a sizable percentage (~30%) of SCLC patient tumors.